A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

Abstract Background This study compared efficacy and safety of TA4415V, a trastuzumab biosimilar, with reference trastuzumab in patients with human epidermal growth factor receptor 2–positive (HER2-positive) early-stage breast cancer treated in the neoadjuvant setting in Iran. Methods Patients were...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Reza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, Nafiseh Ansarinejad, Vahid Moazed, Seyed Mohammad Reza Mortazavizadeh, Mehran Hosseinzadeh, Bayazid Ghaderi, Arash Jenabian, Mojtaba Qadyani, Shirin Haghighat, Abolghasem Allahyari, Mehrzad Mirzania, Mohammad Seghatoleslami, Mehrdad Payandeh, Afsaneh Alikhasi, Hamidreza Kafi, Farhad Shahi
Formaat: Artikel
Taal:English
Gepubliceerd in: BMC 2022-07-01
Reeks:BMC Pharmacology and Toxicology
Onderwerpen:
Breast Cancer
Trastuzumab, biosimilar
Non-inferiority
Randomized clinical trial
Online toegang:https://doi.org/10.1186/s40360-022-00599-x

Internet

https://doi.org/10.1186/s40360-022-00599-x

Gelijkaardige items